The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Sagent Pharmaceuticals met expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share shrank.
Gross margins dropped, operating margins dropped, net margins expanded.
Sagent Pharmaceuticals logged revenue of $49.4 million. The eight analysts polled by S&P Capital IQ expected to see sales of $49.0 million on the same basis. GAAP reported sales were 20% higher than the prior-year quarter's $41.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.13. The eight earnings estimates compiled by S&P Capital IQ anticipated -$0.20 per share. GAAP EPS were -$0.13 for Q3 versus -$0.17 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 14.6%, 220 basis points worse than the prior-year quarter. Operating margin was -8.0%, 20 basis points worse than the prior-year quarter. Net margin was -7.6%, 390 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $57.8 million. On the bottom line, the average EPS estimate is -$0.16.
Next year's average estimate for revenue is $187.2 million. The average EPS estimate is -$0.83.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 11 members out of 15 rating the stock outperform, and four members rating it underperform. Among two CAPS All-Star picks (recommendations by the highest-ranked CAPS members), one give Sagent Pharmaceuticals a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sagent Pharmaceuticals is hold, with an average price target of $19.56.
- Add Sagent Pharmaceuticals to My Watchlist.